Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy. by Nakata, Isao et al.
Title
Two-year outcome of photodynamic therapy combined with
intravitreal injection of bevacizumab and triamcinolone
acetonide for polypoidal choroidal vasculopathy.
Author(s)
Nakata, Isao; Tsujikawa, Akitaka; Yamashiro, Kenji; Otani,
Atsushi; Ooto, Sotaro; Akagi-Kurashige, Yumiko; Ueda-
Arakawa, Naoko; Iwama, Daisuke; Yoshimura, Nagahisa
CitationGraefe's archive for clinical and experimental ophthalmology(2013), 251(4): 1073-1080
Issue Date2013-04
URL http://hdl.handle.net/2433/189826




Triple Therapy for PCV. Nakata I et al. Page 1 
Two-year Outcome of Photodynamic Therapy Combined with Intravitreal Injection 
of Bevacizumab and Triamcinolone Acetonide for Polypoidal Choroidal 
Vasculopathy 
 
Isao Nakata, MD, Akitaka Tsujikawa, MD, Kenji Yamashiro, MD, Atsushi Otani, MD, 5 
Sotaro Ooto, MD, Yumiko Akagi-Kurashige, MD, Naoko Ueda-Arakawa, MD, Daisuke 
Iwama, MD, Nagahisa Yoshimura, MD 
 
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School 
of Medicine, Kyoto, Japan 10 
 
Corresponding author: Akitaka Tsujikawa, MD, Department of Ophthalmology, Kyoto 
University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan  
Tel: +81-75-751-3260; Fax: +81-75-752-0933; E-mail: tujikawa@kuhp.kyoto-u.ac.jp 
15 
*Manuscript_nonhighlighted
Click here to download Manuscript: GraefesArchivesReRe-submit120606_nonhighlight.doc 
Triple Therapy for PCV. Nakata I et al. Page 2 
Abstract 
 
Purpose:  To compare the two-year results after photodynamic therapy (PDT) alone and 
PDT combined with intravitreal injections of bevacizumab and triamcinolone acetonide 
(triple therapy) for polypoidal choroidal vasculopathy (PCV). 5 
Methods:  We retrospectively reviewed the medical records of 40 consecutive patients 
(40 eyes) with subfoveal PCV.  Of these 40 eyes, 16 were treated with PDT alone and 
24 were treated with triple therapy. 
Results:  The change in visual acuity in the triple therapy group was significantly better 
than that in the PDT group (P < 0.001).  At 24 months, improvement in visual acuity was 10 
seen in only 2 eyes (12.5%) of the PDT group while it was seen in 10 eyes (41.7%) of the 
triple therapy group.  Retreatment was given to 12 eyes (75.0%) in the PDT group and 
to 9 eyes (37.5%) in the triple therapy group, although the retreatment-free period was 
significantly longer in the triple therapy group than in the PDT group (P < 0.001).  
Post-treatment vitreous hemorrhage was seen in only two eyes (12.5%), all of which 15 
were in the PDT group. 
Conclusion:  Compared with PDT alone, triple therapy appears to reduce the 
postoperative hemorrhagic complications and recurrences of PCV and to improve the 
two-year visual outcomes of PCV. 
20 
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Introduction 
 
Previously, photodynamic therapy (PDT) with verteporfin was used primarily for the 
treatment of classic choroidal neovascularization (CNV) associated with age-related 
macular degeneration (AMD) [1], while today, intravitreal injections of anti-vascular 5 
endothelial growth factor (VEGF) agents (bevacizumab or ranibizumab) have become 
the principal treatment for exudative AMD [2-4].  Three monthly injections of anti-VEGF 
agents often lead to visual acuity (VA) improvement, but after these initial injections, 
repeated injections are usually required in order to maintain initial visual recovery.  
However, repeated injections increase the risk of ophthalmic and systemic adverse 10 
events, such as endophthalmitis and stroke [5].  To achieve better visual outcomes with 
fewer treatments, several reports have shown promising short-term effects of PDT 
combined with intravitreal injection of bevacizumab and a steroid (triamcinolone 
acetonide [TA] or dexamethasone) for exudative AMD [6,7]. 
     Polypoidal choroidal vasculopathy (PCV) is now recognized as a distinct clinical 15 
entity, differing in many ways from exudative AMD [8].  PCV is characterized by a 
branching vascular network that terminates in polypoidal lesions seen on indocyanine 
green angiography (IA), and is more common in Asians than in Caucasions [9,10].  It 
has been reported that the treatment effects of anti-VEGF agents on the vascular lesions 
of PCV are limited in short-term follow-up [11,12].  In contrast, a number of studies have 20 
shown encouraging results of PDT for the treatment of PCV.  A small number of 
sessions of PDT causes regression of the polypoidal lesions and often results in stable, 
or even improved VA [13-15].  Subsequent reports, however, have shown extensive 
hemorrhagic complications and recurrences of the polypoidal lesions after the initially 
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successful treatment with PDT [16,17]. 
     Recently, PDT combined with anti-VEGF agents has been reported to improve the 
short-term visual outcome in PCV, compared with PDT alone [18-20].  In addition, this 
combination therapy has been suggested to reduce the risk of postoperative hemorrhagic 
complications [18].  Furthermore, it has been reported that TA suppresses the early 5 
proangiogenic response of retinal pigment epithelium (RPE) cells after PDT treatment 
[21], and that the intravitreal injection of TA per se has a suppressive effect on CNV [22].  
For the treatment of PCV, when PDT is combined with an anti-VEGF agent and also with 
TA, this triple therapy might reduce postoperative complications and the recurrence rate, 
and lead to a better visual prognosis.  To date, however, no information is available on 10 
the effects of this triple therapy for PCV.  Accordingly, the study described herein aimed 
to evaluate the long-term results of this triple therapy on symptomatic subfoveal PCV by 
comparing it with PDT alone. 
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Patients and methods 
 
For this retrospective study, we reviewed the medical records of 40 consecutive eyes (40 
patients) with treatment-naïve subfoveal PCV, who were treated with PDT alone or with 
PDT combined with an intravitreal injection of bevacizumab and TA (triple therapy) at 5 
Kyoto University Hospital between September 2004 and December 2008.  PDT alone 
was performed on 16 patients (PDT group) between September 2004 and December 
2007 and PDT combined with bevacizumab and TA was performed on 24 patients (triple 
therapy group) between January 2008 and December 2008.  Inclusion criteria of the 
study were (1) symptomatic PCV in patients older than 50 years, (2) the presence of 10 
subfoveal vascular lesions, (3) best-corrected VA of 20/25 or worse, and (4) a minimum 
follow-up of 24 months after initial treatment.  Exclusion criteria were (1) eyes with other 
macular abnormalities (i.e., AMD, pathologic myopia, idiopathic CNV, presumed ocular 
histoplasmosis, angioid streaks and other secondary CNV), (2) any contraindications for 
fluorescein angiography (FA), IA, or verteporfin, (3) the presence of an RPE tear, (4) any 15 
previous treatment for subfoveal PCV, (5) a history of previous vitrectomy, or (6) any 
other additional therapy during the study period (i.e. anti-VEGF therapy).  This study 
was approved by the Institutional Review Board at Kyoto University Graduate School of 
Medicine and adhered to the tenets of the Declaration of Helsinki.   
     The diagnosis of PCV was based on IA, which shows a branching vascular network 20 
terminating in polypoidal dilation.  In the present study, pseudophakic eyes were 
included.  When both eyes with PCV that were treated with PDT or triple therapy met 
the inclusion criteria, only the eye which was treated initially was included in the current 
study.  Some patients in the PDT group were included in a previous study [17]. 
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     At the initial visit, each patient underwent a comprehensive ophthalmologic 
examination, including measurement of best-corrected VA with a Landolt chart, 
determination of intraocular pressure, indirect ophthalmoscopy, slitlamp biomicroscopy 
with a contact lens, optical coherence tomography examinations and  
FA and IA (HRA-2, Heidelberg Engineering, Dossenheim, Germany). 5 
     In eyes of the PDT group, standard-fluence PDT was performed using a 689 nm 
diode laser unit (Visulas PDT system 690S; Carl Zeiss, Dublin, California, USA) after an 
injection of verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland), according to 
PDT guidelines for AMD [23].  In eyes that received triple therapy, injection of 
bevacizumab (1.25 mg) and TA (2 mg) was performed in a sterile manner and 10 
prophylactic topical antibiotics were applied for 1 week after the injection.  At 3-4 days 
after the intravitreal injection, standard-fluence PDT was performed according to PDT 
guidelines for AMD.  The greatest linear dimension chosen was based on FA and IA, as 
described in detail previously [24].  All polypoidal lesions, the entire branching vascular 
network, and type 2 CNV detected by FA and IA were included.  Serous pigment 15 
epithelial detachment was not included in the lesion area when the absence of underlying 
CNV was confirmed by IA. 
     After the initial treatment, each patient was scheduled to be seen at 3 months, at 
which time they again underwent a comprehensive ophthalmologic examination.  When 
IA showed recurrent or residual polypoidal lesions and exudative change was seen on 20 
ocular coherence tomography (OCT), retreatment with PDT or the triple therapy was 
given according to the initial treatment.  When residual polypoidal lesions were detected 
on IA but no exudative change was seen on OCT, no retreatment was given and the 
patient was reevaluated at the next visit. 
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       All values are presented as mean ± standard deviation.  For statistical analysis, 
best-corrected VA as measured with a Landolt chart was converted to a logarithm of the 
minimum angle of resolution (logMAR).  VA was considered to be improved or 
deteriorated when the logMAR change was greater than 0.2.  On OCT scans, foveal 
thickness was defined as the distance between the inner surface of the neurosensory 5 
retina and the RPE beneath the fovea.  In each group, VA or foveal thickness after 
treatment was studied by one-way repeated measures analysis of variance with the 
Dunnett test.  To compare VA and foveal thickness between the PDT group and the 
triple therapy group, two-factor repeated measures analysis of variance was used.  The 
retreatment-free period was calculated from the date of the initial therapy to the date 10 
when the treating physician determined the necessity of retreatment by PDT or by triple 
therapy.  Survival analysis using Kaplan-Meier methods was used to compare the 
difference in the retreatment-free period after initial treatment between the PDT and the 
triple therapy groups.  In patients who underwent no retreatment by either PDT or triple 
therapy, the retreatment-free period was censored at 2 years of follow-up.  Descriptive 15 
statistics for all demographic and clinical variables were calculated and comparisons 
made using the unpaired t-test for means with continuous data (e.g., age) and the 
Chi-squared test for categorical data (e.g., gender).  Statview version 5.0 software (SAS 
Institute, Inc., Cary, NC, USA) was used for statistical analyses.  A P value < 0.05 was 
considered to be statistically significant. 20 
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Results 
 
In the study described herein, a total of 40 patients with treatment-naïve PCV were 
evaluated; 16 eyes that received only treatment with PDT (PDT group) and 24 eyes that 
received only triple therapy (triple therapy group) during the 24-month study period.  5 
Table 1 shows baseline characteristics of each group.  There were no significant 
differences in age, gender, or baseline VA between the two groups.  However, baseline 
foveal thickness of the triple therapy group was significantly larger than were those of the 
PDT group, and the rate of serous retinal detachment was also higher in the triple 
therapy group. 10 
     Figure 1a shows the time-course in mean foveal thickness of each group.  In the 
triple therapy group, the mean foveal thickness decreased immediately after initiation of 
treatment and remained throughout the 2-year follow-up period.  Figure 1b shows the 
time-course of mean VA in each group.  In the PDT group, there was no significant 
improvement of VA after initiation of treatment; in fact, mean VA was significantly 15 
decreased (+0.25 ± 0.45) at 24 months (P = 0.041).  Alternatively, VA somewhat 
improved after initiation of treatment in the triple therapy group, while the improvement 
was not statistically significant.  Some improvement was maintained throughout the 
2-year follow-up period. 
     Figure 2 shows the change in mean VA from baseline in each group.  The mean 20 
change in VA in the triple therapy group was significantly better than that in the PDT 
group (P < 0.001).  At 24 months after initial treatment, mean change in VA in the triple 
therapy group (-0.10 ± 0.32) was significantly better than that in the PDT group (0.25 ± 
0.45, P = 0.007).  Figure 3 shows the percentage of eyes with improved or decreased 
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VA at 24 months; improvement in VA was seen in 2 eyes (12.5%) of the PDT group and in 
10 eyes (41.7%) of the triple therapy group, and reduction in VA was seen in 9 eyes 
(56.3%) of the PDT group and in 5 eyes (20.1%) of the triple therapy group.  Thus, 
improvement in VA was seen more frequently in the triple therapy group (P = 0.044). 
     Table 2 summarizes final characteristics and complications during the study period.  5 
In both groups, the polypoidal lesions disappeared after treatment (Figure 4).  At 24 
months, complete disappearance of the polypoidal lesions was confirmed in 13 eyes 
(81.3%) in the PDT group and in 22 eyes (91.7%) of the triple therapy group.  In the 
triple therapy group, 15 eyes (62.5%) of the triple therapy group and 4 eyes (25.0%) of 
PDT group underwent a single session of PDT during the 24-month study period. (P = 10 
0.020)  Retreatment by PDT was done in 12 eyes (75.0%) in that group, and 9 eyes 
(37.5%) in the triple therapy group received retreatment by triple therapy (Figure 5).  
The mean numbers of treatment were 2.19 ± 0.91 in the PDT group and 1.50 ± 0.78 in 
the triple therapy group (P = 0.015).  Figure 6 shows the overall survival analysis curve 
for the retreatment-free periods in each group, which was significantly longer in the triple 15 
therapy group (20.6 ± 6.8 months) than in the PDT group (11.7 ± 8.6 months, P < 0.001). 
     In the current study, two eyes (12.5%) in the PDT group developed cataract and 
underwent surgery during the study period; additionally, one eye (4.2%) in the triple 
therapy group (P = 0.327) underwent similar surgery.  In the PDT group, two eyes 
(12.5%) developed a vitreous hemorrhage and one eye developed an RPE tear during 20 
the study period, while no eye in the triple therapy group developed a vitreous 
hemorrhage.  No eye underwent glaucoma surgery for their ocular hypertension after 
intravitreal injections of TA. 
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Discussion 
 
Several investigators have reported the short-term outcomes of anti-VEGF agents for 
the treatment of PCV, and have shown the limited effect of these agents on the vascular 
lesions of PCV, even though the anti-VEGF agents reduced the exudative change that 5 
was due to PCV.  It has been reported that complete resolution of the polypoidal 
lesions was achieved in only 16.1% of eyes, with a mean of 3.3 injections of 
bevacizumab over a 12 month period [25].  In an earlier report, although monthly 
injections of ranibizumab successfully reduced the exudative manifestations of PCV, a 
reduction in the polypoidal lesions was seen in only 33% of eyes [11]. 10 
     In contrast, a number of studies have shown encouraging results of PDT for the 
vascular lesions of PCV, with complete regression of the polypoidal lesions achieved in 
many cases with fewer sessions.  In a report by Chan et al.[26], PDT led to complete 
regression of the polypoidal lesions in 95% of eyes with PCV, and resulted in either 
stable or improved VA one year after treatment in 95% of eyes.  However, a year or 15 
more after successful treatment with PDT, recurrences of the polypoidal lesions 
sometimes cause a substantial decrease in VA.  Using Kaplan-Meier methods, 
Yamashiro et al. reported that the recurrence of polypoidal lesions after successful PDT 
treatment was estimated to be 11.5% at 15 months, 20.4% at 18 months, and 38.8% at 
21 months [16].  Thus, the recurrence of polypoidal lesions after PDT is a major 20 
problem in the treatment of PCV. 
     In the combination therapy, anti-VEGF agents, which can cause rapid reduction of 
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the exudative change, are thought to contribute to the visual recovery that is associated 
with regression of the polypoidal lesions induced by PDT.  Previous experimental 
studies have shown increased expression of VEGF shortly after PDT treatment [27,28], 
which suggests that an intravitreal injection of bevacizumab before PDT may well exert 
a protective effect.  Regarding the injection of TA, Okubo and colleagues reported a 5 
case of PCV successfully treated with trans-Tenons retrobulbar injection of TA [29], and 
Mukai and colleagues reported the protective effects of TA against occlusion of the 
choriocapillaris which was induced by PDT [30].  However, Lai et al. reported that the 
adjunctive use of TA during PDT did not appear to result in additional benefit for the 
treatment of PCV [31], so the effect of TA on PCV remains controversial. 10 
     In the current study, the PDT group showed no significant improvement in VA after 
initiation of treatment; mean VA was significantly decreased at 24 months.  In the triple 
therapy group, however, VA was improved at 3 months after treatment and mean VA 
was improved by -0.11 (logMAR) at 6 months and by -0.09 (logMAR) at 12 months.  In 
this triple therapy group, although improvement was not statistically significant, at least 15 
some improvement in VA was maintained throughout the 2-year follow-up period.  At 
24 months, VA improvement was achieved in only 12.5% of eyes in the PDT group and 
in 41.7% in the triple therapy group (P = 0.044), so, based on our findings, triple therapy 
for PCV, compared to PDT alone, results in more rapid visual recovery and improved 
visual outcome at 24 months. 20 
     In our case series, both PDT alone and the triple therapy successfully reduced the 
polypoidal lesions and the exudative change, with complete disappearance of the 
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polypoidal lesions confirmed at 24 months in 81.3% of cases in the PDT group and in 
91.7% of cases in the triple therapy group.  There were significant differences in the 
number of eyes with a recurrence and in the number of PDT treatments between the 
two groups.  Furthermore, the retreatment-free period was significantly longer in the 
triple therapy group (20.6 ± 6.8 months) than in the PDT group (11.7 ± 8.6 months). 5 
     Following treatment for PCV, one of the most vision-threatening complications of 
PDT is extensive hemorrhage.  A previous report of PCV treated with PDT indicated 
that postoperative subretinal hemorrhage was seen in 28 of 91 eyes, and that bleeding 
resulted in a vitreous hemorrhage in 6 eyes [32].  In the current study, no eye in the 
triple therapy group developed a vitreous hemorrhage, although two eyes in the PDT 10 
group developed a vitreous hemorrhage.  Recent reports by Gomi et al.[18] and by 
Sato et al.[19] suggested a lower incidence of subretinal hemorrhage after PDT when it 
was combined with bevacizumab, and it has been reported that the vasoconstrictive 
effect of bevacizumab may contribute to the suppression of postoperative hemorrhages 
[33]. 15 
     Major limitations of the current study are its retrospective nature and its relatively 
small sample size.  In addition, there were some statistical differences between the 
two groups, including baseline foveal thickness and the rate of serous retinal 
detachment, which may affect the response to treatment.  Furthermore, this study was 
not a randomized, comparative trial.  However, selection bias is small as both groups 20 
consisted of consecutive eyes that were treated at different time periods.  Our findings 
suggest that intravitreal injection of bevacizumab and TA combined with PDT improves 
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the 2-year visual outcome of PCV and may reduce postoperative hemorrhagic 
complications and the recurrence rate.  However, because our findings are based on 
an observation period of only 24 months, it remains unclear whether triple therapy has a 
long-term effect. 
     Another limitation is that the safety and efficacy of the triple therapy were not 5 
compared with PDT combined with anti-VEGF therapy.  Recently, the EVEREST study 
has shown the 6-month effects of PDT in combination with ranibizumab for PCV [34], in 
which the eyes treated with PDT combined with ranibizumab achieved the highest 
gains at 6 months.  However, it remains unclear whether this combination therapy 
reduces the recurrence of polypoidal lesions after successful initial treatment.  Further 10 
prospective, randomized, long-term studies are necessary to determine the efficacy and 
safety of triple therapy for PCV. 
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Figure legends  
 
Fig. 1.  Mean foveal thickness (A) and mean visual acuity (B) in eyes with polypoidal 
choroidal vasculopathy treated with photodynamic therapy (PDT group) or with PDT 
combined with intravitreal injections of bevacizumab and triamcinolone acetonide (triple 5 
therapy group).  Visual acuity is shown in logMAR fashion.  *P < 0.05, compared with 
pretreatment values.  Error bars represent the standard error. 
 
Fig. 2.  Change in visual acuity in eyes with polypoidal choroidal vasculopathy treated 
with photodynamic therapy (PDT group) or with a combination of PDT and intravitreal 10 
injection of bevacizumab and triamcinolone acetonide (triple therapy group).  Change in 
visual acuity in eyes treated with triple therapy was significantly better than that in eyes 
treated with PDT alone (P < 0.001).  Visual acuity is shown in logMAR fashion.  *P < 
0.05, compared with values in the PDT group.  Error bars represent the standard error. 
  15 
Fig. 3.  Percentages of eyes with improved and deteriorated visual acuity at 24 months 
after treatment.  All eyes with polypoidal choroidal vasculopathy were treated with 
photodynamic therapy (PDT group) or PDT combined with intravitreal injection of 
bevacizumab and triamcinolone acetonide (triple therapy group).  Visual acuity was 
considered to be improved or deteriorated when the change in logMAR units was greater 20 
than 0.2.  Improvement of visual acuity was seen more frequently in the triple therapy 
group (P = 0.044). 
 
Fig. 4.  Polypoidal choroidal vasculopathy successfully treated with photodynamic 
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therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide 
(triple therapy).  A Initial fundus photograph (left) shows reddish-orange nodules and 
fibrin exudate (20/50 OS).  Indocyanine green angiography (middle) shows a branching 
vascular network that terminates in polypoidal lesions.  A vertical optical coherence 
tomography section through the fovea (right) reveals sharp protrusions of the retinal 5 
pigment epithelium due to polypoidal lesions (arrows).  A branching vascular network is 
seen as flat protrusions (arrowheads).  B Three months after triple therapy.  No 
polypoidal lesions are seen on indocyanine green angiogram.  A branching vascular 
network is still seen.  Protrusions due to polypoidal lesions have become flattened 
(20/60 OS).  C 12 months after treatment, no recurrence is seen (20/50 OS). 10 
 
Fig. 5.  Recurrence of polypoidal lesions after successful treatment with photodynamic 
therapy of polypoidal choroidal vasculopathy.  A Initial fundus photograph (left) shows a 
reddish-orange nodule with a hard exudate and with a subretinal hemorrhage (20/40 OD).  
Indocyanine green angiography (right) shows a branching vascular network that 15 
terminates in polypoidal lesions.  B Three months after photodynamic therapy.  
Reddish-orange nodules and polypoidal lesions haves regressed (20/30 OD).  C At 12 
months after treatment, recurrence has occurred.  Fundus photograph shows pigment 
epithelial detachments with surrounding subretinal hemorrhage and hard exudate 
(20/100 OD).  Polypoidal lesions have recurred at the terminus of the remaining 20 
branching vascular network.  D At 3 months after retreatment with photodynamic 
therapy, pigment epithelial detachments and polypoidal lesions have completely 
regressed (20/70 OD). 
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Fig. 6.  Overall survival curve for the retreatment-free period in both treatment groups.  
Eyes with polypoidal choroidal vasculopathy were treated with either photodynamic 
therapy (PDT group) or PDT combined with intravitreal injection of bevacizumab and 
triamcinolone acetonide (triple therapy group).  The period until the treating physician 
opted to perform additional treantment was significantly longer in the triple therapy 5 
group than in the PDT group (P < 0.001). 

















Number of patients 16 24  
Age (years) 73.3 ± 9.9 73.7 ± 5.8 0.887* 
Gender (female/male) 5/11 6/18 0.665† 
Initial visual acuity (logMAR) 0.36 ± 0.13 0.50 ± 0.31 0.119* 
Initial foveal thickness (μm) 264.9 ± 87.4 392.1 ± 129.5 0.002* 
Cystoid macular edema  4 (25.0%) 11 (45.8%) 0.182† 
Serous retinal detachment  11 (68.8%) 24 (100%) 0.003† 
Subretinal hemorrhage  8 (50.0%) 7 (29.2%) 0.182† 
Pigment epithelial detachment  13 (81.3%) 23 (95.8%) 0.132† 
Greatest linear dimension (μm) 2584 ± 998 3193 ± 1194 0.101* 
logMAR, logarithm of the minimum angle of resolution. 
* Unpaired t-test. 
† Chi-squared test. 
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Number of patients 16 24  
Final visual acuity (logMAR) 0.62 ± 0.43 0.40 ± 0.38 0.099* 
Final foveal thickness (μm) 283 ± 204 230 ± 66 0.234* 
Final conditions    
    Cystoid macular edema 5 (31.3%) 0 (0%) 0.003† 
    Serous retinal detachment 5 (31.3%) 0 (0%) 0.003† 
    Subretinal hemorrhage 2 (12.5%) 1 (4.2%) 0.327† 
    Pigment epithelial detachment 11 (68.8%) 5 (20.8%) 0.002† 
    Polypoidal lesions 3 (18.8%) 2 (8.3%) 0.385† 
Complications    
    Cataract 2 (12.5%) 1 (4.2%) 0.327† 
    Suprachoroidal hemorrhage 1 (6.3%) 0 (0%) 0.215† 
    Vitreous hemorrhage 2 (12.5%) 0 (0%) 0.076† 
    Tear of retinal pigment epithelium 1 (6.3%) 0 (0%) 0.215† 
Number of photodynamic therapy or 
triple therapy sessions (range) 
2.19 ± 0.91 
(1-3) 
1.50 ± 0.78 
(1-3) 
0.015* 
Retreatment-free period (months) 11.7 ± 8.6 20.6 ± 6.8 < 0.001‡ 
logMAR, logarithm of the minimum angle of resolution; VEGF, vascular endothelial growth 
factor. 
* Unpaired t-test. 
† Chi-squared test. 
‡ Survival analysis. 
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